Bioaccumulation/bioconcentration of pharmaceutical active compounds in aquatic organisms: Assessment and factors database
Metadata
Show full item recordAuthor
Gómez Regalado, María del Carmen; Martín, Julia; Santos, Juan Luis; Aparicio, Irene; Alonso, Esteban; Zafra Gómez, AlbertoEditorial
Elsevier
Materia
Emerging pollutants Biota Exposure Bioconcentration factor Bioaccumulation factor
Date
2022-12-05Referencia bibliográfica
M.C. Gómez-Regalado et al. Bioaccumulation/bioconcentration of pharmaceutical active compounds in aquatic organisms: Assessment and factors database. Science of the Total Environment 861 (2023) 160638[http://dx.doi.org/10.1016/j.scitotenv.2022.160638]
Sponsorship
MCIN/AEI/10.13039/501100011033/ (grant: PID2020-117641RB-I00); Consejería de Economía, Conocimiento, Empresas; Universidad (Spanish regional Government of Andalucia); European funding from ERDF 2014–2020 program (grants B.RNM.362.UGR20 and P20_00556)Abstract
There is increasing evidence that the presence of certain pharmaceuticals in the environment leads to biota exposure
and constitute a potential risk for ecosystems. Bioaccumulation is an essential focus of risk assessment to evaluate at
what degree emerging contaminants are a hazard both to the environment and the individuals that inhabit it. The
main goals of the present review are 1) to summarize and describe the research and factors that should be taken
into account in the evaluation of bioaccumulation of pharmaceuticals in aquatic organisms; and 2) to provide a database
and a critical review of the bioaccumulation/bioconcentration factors (BAF or BCF) of these compounds in organisms
of different trophic levels.
Most studies fall into one of two categories: laboratory-scale absorption and purification tests or field studies and, to a
lesser extent, large-scale, semi-natural system tests. Although in the last 5 years there has been considerable progress in
this field, especially in species of fish andmolluscs, research is still limited on other aquatic species like crustaceans or
algae. This revision includes >230 bioconcentration factors (BCF) and >530 bioaccumulation factors (BAF), determined
for 113 pharmaceuticals. The most commonly studied is the antidepressant group, followed by diclofenac
and carbamazepine. There is currently no reported accumulation data on certain compounds, such as anti-cancer
drugs. BCFs are highly influenced by experimental factors (notably the exposure level, time or temperature). Field
BAFs are superior to laboratory BCFs, highlighting the importance of field studies for reliable assessments and in
true environmental conditions. BAF data appears to be organ, species and compound-specific. The potential impact
on food web transfer is also considered. Among different aquatic species, lower trophic levels and benthic organisms
exhibit relatively higher uptake of these compounds.